

# Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

NCT07089121

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Cartesian Therapeutics
Enrollment	50 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- At least age 12
- definitive diagnosis of childhood-onset systemic lupus erythematosus, juvenile Myasthenie gravis, juvenile dermatomyositis and AAV
- Signs and symptoms of moderate disease
- History of systemic treatment
- Parent/Guardian/Patient must be able to give written informed consent

### Exclusion (13)

- Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient;
- Abnormal PT/INR or PTT increased  $\gt$  1.5-fold or patient is on anticoagulation therapy (except in cases of elevated PTT with documented lupus anticoagulant; or in patients who have been on stable doses of anticoagulation therapy for more than 6 months of VTE diagnosis; or in patients on stable doses of anticoagulation therapy for at least 8 weeks of atrial fibrillation diagnosis; these conditions will not be exclusionary unless, in the investigator's opinion, they make participation in the study unsafe);
- ANC  $\lt$  1000 cells/microliter ;
- Hemoglobin  $\lt$  8.0 g/dL ;
- Platelets  $\lt$  50,000/mm<sup>3</sup> (NOTE: platelet transfusions are permissible);
- ... and 8 more (see full listing online)

## Locations (2 total)

---

- H01- Children's National Hospital, Washington D.C., District of Columbia, United States
- H03- Washington University School of Medicine, St Louis, Missouri, United States